Trials / Completed
CompletedNCT05822843
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
A Phase I, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of Anti-BAFFR mAb(Monoclonal Antibody), ESG206 in Subjects With B-cell Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ESG206 | Administered via intravenous (IV) infusion |
Timeline
- Start date
- 2023-08-02
- Primary completion
- 2025-01-22
- Completion
- 2025-01-22
- First posted
- 2023-04-21
- Last updated
- 2025-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05822843. Inclusion in this directory is not an endorsement.